Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriCAR-T-CD19 for relapsed or refractory CD19-positive non-Hodgkin lymphoma
ChiCTR1800014528Phase 2Recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Jan 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19-TriCAR-T in non-Hodgkin lymphoma (NHL), sponsored by Hunan Provincial People's Hospital. Primary endpoint: Safety. Started Jan 2018; status: recruiting.
02
Drugs
CD19-TriCAR-T
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ChiCTR1800014528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014528.